HopeStage
Study directory

Depression studies

Depression involves persistent low mood or loss of interest, often with tiredness and changes in sleep or appetite.

Back to overview
More filters: keywords, city, remote
7264studies shown
Showing 109-120 of 7,264
Device study icon
RecruitingNCT05813093

Interleaved TMS-fMRI in Ultra-treatment Resistant Depression

Official study title

Interleaved TMS-fMRI to Evaluate Intermittent Theta-burst and Dorsolateral Prefrontal Circuit Engagement in Ultra-treatment Resistant Depression

In Toronto
DepressionDevice studyAges 20–65
Countries
Canada
Sponsor
Sunnybrook Health Sciences Centre
Device study icon
RecruitingNCT05952674

Treatment Resistant Depression and Vagus Nerve Stimulation

Official study title

Resistant Depression and Vagus Nerve Stimulation : a Medico-economic, Multicenter, Randomized and Open Trial

Multiple locations, including Bordeaux
DepressionDevice studyAges 18+
Countries
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Behavioral study icon
Enrolling By InvitationNCT06633263

Combined Effect of TCC-I and BATD on Depressive Symptoms and Insomnia

Official study title

Combined Effect of Cognitive Behavioral Therapy for Insomnia and a Behavioral Activation Program for Depression on Depressive Symptoms and Insomnia : A Multiple Case Study

This study is by invitation only.

In Liège
DepressionBehavioural studyAges 18–67
Countries
Belgium
Sponsor
University of Liege
Drug study icon
Not Yet RecruitingACTRN12610000710022

An 8 week placebo controlled study investigating the role of adjunctive bioactive lipids specifically; docosahexaenoic acid (DHA) versus eicosapentaenoic acid (EPA) in Major Depressive Disorder - with a 6 week open label extension of DHA in patients aged 18-65years.

Official study title

An 8 week randomised, double-blind, placebo controlled trial investigating the role of adjunctive bioactive lipids specifically; docosahexaenoic acid (DHA) versus eicosapentaenoic acid (EPA) in Major Depressive Disorder - with a 6 week open label extension of DHA in patients aged 18-65years.

This study isn't recruiting yet.

Location not clearly listed
DepressionInterventional studyAges 18–65
Countries
Sponsor
The Melbourne Clinic
Drug study icon
RecruitingNCT07065240

SPT-300 (GlyphAllo) for depression

What is this study about?

Researchers are comparing SPT-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.

Multiple locations, including Chino
DepressionMedication studyAges 18–65
Countries
United States, Bulgaria, Czechia, + 4 others
Sponsor
Seaport Therapeutics
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.